AU2012308238B2 - Certain chemical entities, compositions, and methods - Google Patents
Certain chemical entities, compositions, and methods Download PDFInfo
- Publication number
- AU2012308238B2 AU2012308238B2 AU2012308238A AU2012308238A AU2012308238B2 AU 2012308238 B2 AU2012308238 B2 AU 2012308238B2 AU 2012308238 A AU2012308238 A AU 2012308238A AU 2012308238 A AU2012308238 A AU 2012308238A AU 2012308238 B2 AU2012308238 B2 AU 2012308238B2
- Authority
- AU
- Australia
- Prior art keywords
- carbonyl
- phenyl
- urea
- quinoxaline
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017218983A AU2017218983B2 (en) | 2011-09-14 | 2017-08-22 | Certain chemical entities, compositions, and methods |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161534390P | 2011-09-14 | 2011-09-14 | |
| US61/534,390 | 2011-09-14 | ||
| US201161535992P | 2011-09-18 | 2011-09-18 | |
| US61/535,992 | 2011-09-18 | ||
| PCT/US2012/055653 WO2013040515A1 (en) | 2011-09-14 | 2012-09-14 | Certain chemical entities, compositions, and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017218983A Division AU2017218983B2 (en) | 2011-09-14 | 2017-08-22 | Certain chemical entities, compositions, and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012308238A1 AU2012308238A1 (en) | 2014-04-17 |
| AU2012308238B2 true AU2012308238B2 (en) | 2017-05-25 |
Family
ID=47883812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012308238A Active AU2012308238B2 (en) | 2011-09-14 | 2012-09-14 | Certain chemical entities, compositions, and methods |
| AU2017218983A Active AU2017218983B2 (en) | 2011-09-14 | 2017-08-22 | Certain chemical entities, compositions, and methods |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017218983A Active AU2017218983B2 (en) | 2011-09-14 | 2017-08-22 | Certain chemical entities, compositions, and methods |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US9518029B2 (https=) |
| EP (2) | EP3332785B1 (https=) |
| JP (2) | JP6093768B2 (https=) |
| CN (3) | CN115403531A (https=) |
| AU (2) | AU2012308238B2 (https=) |
| CA (1) | CA2848506C (https=) |
| WO (1) | WO2013040515A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| ES2725790T3 (es) | 2011-08-26 | 2019-09-27 | Neupharma Inc | Algunas entidades químicas, composiciones, y métodos |
| CN115403531A (zh) * | 2011-09-14 | 2022-11-29 | 润新生物公司 | 作为激酶抑制剂的化学实体、组合物及方法 |
| US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| EP2806874B1 (en) | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
| MX371331B (es) | 2012-04-24 | 2020-01-27 | Vertex Pharma | Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk). |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US9688635B2 (en) | 2012-09-24 | 2017-06-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2014075077A1 (en) * | 2012-11-12 | 2014-05-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| ME03336B (me) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| BR112016005199B1 (pt) | 2013-08-23 | 2022-02-22 | Neupharma, Inc | Certos compostos químicos, composições, e métodos |
| JP6408569B2 (ja) | 2013-10-17 | 2018-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 |
| HRP20210319T1 (hr) | 2014-03-26 | 2021-04-30 | Astex Therapeutics Ltd. | Kombinacije inhibitora fgfr i inhibitora igf1r |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| RU2715236C2 (ru) | 2014-03-26 | 2020-02-26 | Астекс Терапьютикс Лтд | Комбинации |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| EP3353164B1 (en) | 2015-09-23 | 2021-11-03 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| US11155555B2 (en) | 2015-09-23 | 2021-10-26 | Janssen Pharmaceutica Nv | Compounds |
| WO2018035061A1 (en) | 2016-08-15 | 2018-02-22 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| EP3518931A4 (en) | 2016-09-27 | 2020-05-13 | Vertex Pharmaceuticals Incorporated | METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013043935A1 (en) * | 2011-09-21 | 2013-03-28 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4464533A (en) | 1982-11-08 | 1984-08-07 | Ppg Industries, Inc. | Herbicidally active quinoline or quinoxaline benzoate derivatives |
| DE3482180D1 (de) | 1983-10-05 | 1990-06-13 | Basf Ag | Cyclohexenol-derivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses. |
| GB2189238A (en) | 1986-04-15 | 1987-10-21 | Shell Int Research | Heterocyclic phenyl ether compounds |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| US6348461B1 (en) | 1997-09-01 | 2002-02-19 | Kyorin Pharmaceutical Co., Ltd. | 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, addition salts thereof, and processes for the preparation of both |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| WO2002036734A2 (en) | 2000-10-12 | 2002-05-10 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors |
| US7034026B2 (en) | 2001-04-10 | 2006-04-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| US7691866B2 (en) | 2003-10-16 | 2010-04-06 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase |
| DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| MX2007004480A (es) * | 2004-10-15 | 2007-05-08 | Astrazeneca Ab | Quinoxalinas como inhibidores b raf. |
| ES2395952T3 (es) | 2005-03-16 | 2013-02-18 | Toyama Chemical Co., Ltd. | Nuevo derivado del ácido antranílico o una sal del mismo |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| US7749530B2 (en) | 2005-07-13 | 2010-07-06 | Allergan, Inc. | Kinase inhibitors |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2181987B9 (en) * | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
| EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
| NZ586418A (en) | 2007-12-19 | 2012-09-28 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| EP3147281A1 (en) | 2008-03-17 | 2017-03-29 | Ambit Biosciences Corporation | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
| US20100197688A1 (en) | 2008-05-29 | 2010-08-05 | Nantermet Philippe G | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US20130018033A1 (en) | 2009-08-28 | 2013-01-17 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| WO2011068187A1 (ja) | 2009-12-04 | 2011-06-09 | 第一三共株式会社 | キナゾリン誘導体 |
| US8669256B2 (en) | 2010-05-28 | 2014-03-11 | Merck Sharp & Dohme B.V. | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN103619865B (zh) | 2011-02-02 | 2016-10-12 | 苏州润新生物科技有限公司 | 某些化学个体、组合物及方法 |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| EP2726870B1 (en) | 2011-06-29 | 2018-10-03 | Academia Sinica | The capture, purification and release of biological substance using a surface coating |
| CN103875268B (zh) | 2011-08-10 | 2018-03-27 | 爱立信(中国)通信有限公司 | 用于非3gpp接入的hss故障恢复 |
| ES2725790T3 (es) * | 2011-08-26 | 2019-09-27 | Neupharma Inc | Algunas entidades químicas, composiciones, y métodos |
| CN115403531A (zh) | 2011-09-14 | 2022-11-29 | 润新生物公司 | 作为激酶抑制剂的化学实体、组合物及方法 |
| US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
| WO2013063221A1 (en) | 2011-10-25 | 2013-05-02 | Janssen Pharmaceutica Nv | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
| EP2806874B1 (en) | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
| US9688635B2 (en) | 2012-09-24 | 2017-06-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2014075077A1 (en) | 2012-11-12 | 2014-05-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
-
2012
- 2012-09-14 CN CN202210707660.8A patent/CN115403531A/zh active Pending
- 2012-09-14 CA CA2848506A patent/CA2848506C/en active Active
- 2012-09-14 CN CN201280055629.5A patent/CN104080455B/zh active Active
- 2012-09-14 US US14/344,709 patent/US9518029B2/en active Active
- 2012-09-14 WO PCT/US2012/055653 patent/WO2013040515A1/en not_active Ceased
- 2012-09-14 EP EP17195141.1A patent/EP3332785B1/en active Active
- 2012-09-14 CN CN201810724450.3A patent/CN108794411B/zh active Active
- 2012-09-14 JP JP2014530915A patent/JP6093768B2/ja active Active
- 2012-09-14 EP EP12831538.9A patent/EP2755657B1/en active Active
- 2012-09-14 AU AU2012308238A patent/AU2012308238B2/en active Active
-
2016
- 2016-11-04 US US15/343,935 patent/US9822081B2/en active Active
-
2017
- 2017-02-13 JP JP2017024144A patent/JP2017082011A/ja not_active Withdrawn
- 2017-08-22 AU AU2017218983A patent/AU2017218983B2/en active Active
- 2017-10-16 US US15/785,146 patent/US10065932B2/en active Active
-
2019
- 2019-03-20 US US16/359,654 patent/US10759766B2/en active Active
-
2020
- 2020-07-21 US US16/934,907 patent/US20210040048A1/en not_active Abandoned
-
2021
- 2021-12-10 US US17/547,660 patent/US20220251049A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013043935A1 (en) * | 2011-09-21 | 2013-03-28 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013040515A1 (en) | 2013-03-21 |
| EP2755657A1 (en) | 2014-07-23 |
| CN104080455B (zh) | 2018-07-31 |
| JP2014530194A (ja) | 2014-11-17 |
| US10065932B2 (en) | 2018-09-04 |
| US20220251049A1 (en) | 2022-08-11 |
| AU2012308238A1 (en) | 2014-04-17 |
| US20170183316A1 (en) | 2017-06-29 |
| CN115403531A (zh) | 2022-11-29 |
| EP3332785B1 (en) | 2020-05-06 |
| US20150158826A1 (en) | 2015-06-11 |
| CN108794411B (zh) | 2022-06-07 |
| CN104080455A (zh) | 2014-10-01 |
| US20200055828A1 (en) | 2020-02-20 |
| CN108794411A (zh) | 2018-11-13 |
| EP3332785A1 (en) | 2018-06-13 |
| JP6093768B2 (ja) | 2017-03-08 |
| EP2755657A4 (en) | 2015-03-25 |
| EP2755657B1 (en) | 2017-11-29 |
| AU2017218983A1 (en) | 2017-09-07 |
| US9518029B2 (en) | 2016-12-13 |
| US20210040048A1 (en) | 2021-02-11 |
| CA2848506A1 (en) | 2013-03-21 |
| AU2017218983B2 (en) | 2019-05-02 |
| US9822081B2 (en) | 2017-11-21 |
| JP2017082011A (ja) | 2017-05-18 |
| US20180134669A1 (en) | 2018-05-17 |
| US10759766B2 (en) | 2020-09-01 |
| CA2848506C (en) | 2020-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012308238B2 (en) | Certain chemical entities, compositions, and methods | |
| AU2012300317B2 (en) | Certain chemical entities, compositions, and methods | |
| EP2757885B1 (en) | Certain chemical entites, compositions, and methods | |
| US10047059B2 (en) | Substituted quinoxalines for inhibiting kinase activity | |
| WO2014047648A1 (en) | Certain chemical entities, compositions, and methods | |
| WO2013112950A2 (en) | Certain chemical entities, compositions, and methods | |
| WO2013049701A1 (en) | Certain chemical entities, compositions, and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |